60 rue de Wattignies
Paris 75012
France
33 1 40 26 04 70
https://www.nanobiotix.com
Settore/i:
Settore:
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Laurent Levy Ph.D. | Co-Founder, President of the Executive Board & CEO | 713,87k | N/D | 1973 |
Mr. Bart Van Rhijn | CFO & Member of Executive Board | 628,49k | N/D | 1973 |
Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Executive Board | 354,9k | N/D | 1974 |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
L'ISS Governance QualityScore di Nanobiotix S.A. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 7; retribuzione: 10.